Search Result

Isoforms Recommended:	mGluR5

Results for "

mGluR5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (4) Amyloid-β (4) Apoptosis (3) Calcium Channel (5) Caspase (1) Endogenous Metabolite (5) ERK (6) GABA Receptor (6) iGluR (3) Isotope-Labeled Compounds (1) mGluR (68) Mitochondrial Metabolism (1) nAChR (2) NF-κB (3) Phosphatase (1) PKC (2) Reference Standards (15) Small Interfering RNA (siRNA) (3) Trk Receptor (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (73)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1363

β-Amyloid (1-42), human TFA Maximum Cited Publications 24 Publications Verification Amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

HY-P1363A

β-Amyloid (1-42), human Maximum Cited Publications 24 Publications Verification Amyloid β-peptide (1-42) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

HY-P1363B

β-Amyloid (1-42), human, HFIP-treated Maximum Cited Publications 24 Publications Verification	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

HY-13206

MTEP hydrochloride 3 Publications Verification	mGluR	Neurological Disease
MTEP hydrochloride is a potent, non-competitive and highly selective *mGluR5* antagonist, with an IC₅₀ of 5 nM and a K_i of 16 nM. MTEP hydrochloride shows antidepressant and anxiolytic-like effects. MTEP hydrochloride can be used for Parkinson's disease research .

HY-15257

Mavoglurant 4 Publications Verification AFQ056	mGluR	Neurological Disease
Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active *mGluR5* antagonist, with an IC₅₀ of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14569

CDPPB 1 Publications Verification	mGluR Akt ERK Caspase Mitochondrial Metabolism	Neurological Disease Inflammation/Immunology Cancer
CDPPB is a selective, orally active and brain-penetrant *mGluR5* allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease ^[5] .

HY-15445

CTEP 2 Publications Verification RO 4956371; mGluR5 inhibitor	mGluR	Neurological Disease
CTEP (RO 4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC₅₀ of 2.2 nM, and shows > 1000-fold selectivity over other mGlu receptors. CTEP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12598

(S)-3,5-DHPG	mGluR	Neurological Disease
(S)-3,5-DHPG is a weak, but selective group I metabotropic glutamate receptors (mGluRs) agonist with K_i values of 0.9 μM and 3.9 μM for mGluR1a and mGluR5a, respectively . (S)-3,5-DHPG exhibits anxiolytic activity in rats subjected to hypoxia .

HY-B0340

Nefiracetam DM9384; DZL-221	nAChR iGluR mGluR PKC GABA Receptor Calcium Channel	Neurological Disease
Nefiracetam is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), *mGluR5, PKC, gamma-aminobutyric acid (GABA*), and N/L-type Ca ²⁺ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research ^[5] .

HY-15446

Basimglurant 1 Publications Verification RG7090; RO4917523	mGluR	Neurological Disease
Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a K_i of 1.4 nM (against [ ³H]-ABP688 (HY-110141)) and 35.6 nM (against [ ³H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc .

HY-14859

Dipraglurant ADX48621	mGluR	Neurological Disease
Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant *mGluR5* negative allosteric modulator (NAM), with an IC₅₀ of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100786

DL-AP3 1 Publications Verification	Endogenous Metabolite mGluR Phosphatase	Neurological Disease Cancer
DL-AP3 is a competitive *mGluR1* and *mGluR5* antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect .

HY-100804

L-Cysteinesulfinic acid 2 Publications Verification	mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-101364

CHPG 4 Publications Verification	mGluR NF-κB ERK Akt	Cardiovascular Disease Inflammation/Immunology
CHPG is a selective *mGluR5* agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways .

HY-13206A

MTEP 3 Publications Verification	mGluR	Neurological Disease
MTEP is a potent, non-competitive and highly selective *mGluR5* antagonist, with an IC₅₀ of 5 nM and a K_i of 16 nM. MTEP shows antidepressant and anxiolytic-like effects. MTEP can be used for Parkinson's disease research . MTEP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13058

ADX-47273 1 Publications Verification	mGluR	Neurological Disease
ADX-47273 is a potent, selective and brain-penetrant *mGluR5* positive allosteric modulator (PAM), with an EC₅₀ of 0.17 μM for potentiation of glutamate (50 nM) response. ADX-47273 has antipsychotic and procognitive activities .

HY-155352

mGluR5 antagonist-1	mGluR	Neurological Disease
mGluR5 antagonist-1 is an orally active *mGluR5* antagonist with an IC₅₀ value of 11.5 nM. mGluR5 antagonist-1 has anti-depressant effect. mGluR5 antagonist-1 can be used for the study of depressive disorder .

HY-122559

BMS-984923	mGluR	Neurological Disease
BMS-984923, a potent *mGluR5* silent allosteric modulator (SAM), with exquisite binding affinity (K_i = 0.6 nM), exhibits good oral bioavailability and BBB penetration. BMS-984923 potently inhibits the PrPC-mGluR5 interaction and prevents pathological Aβo signaling without affecting physiological glutamate signaling .

HY-W017230

L-Cysteinesulfinic acid monohydrate 2 Publications Verification	mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-101364A

CHPG sodium salt 4 Publications Verification	mGluR NF-κB ERK Akt	Neurological Disease Inflammation/Immunology
CHPG sodium salt is a selective *mGluR5* agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways. .

HY-100371

(RS)-MCPG 1 Publications Verification alpha-MCPG	mGluR	Neurological Disease
(RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons .

HY-101478

Fenobam	mGluR Apoptosis	Neurological Disease Cancer
Fenobam is a selective and orally active *mGluR5* antagonist (IC₅₀=84 nM) that can penetrate the blood-brain barrier. Fenobam shows the K_d values of 54 nM and 31 nM on rat and human recombinant *mGlu5* receptors, respectively. Fenobam has anxiolytic activity, inhibits self-administration behavior in mice, and induces apoptosis in cancer cells. Fenobam can be used for research on neurological diseases, cancer and drug addiction .

HY-14612

CPPHA	mGluR	Neurological Disease
CPPHA is potent and selective positive allosteric modulator (PAM) of the *mGluR5* and *mGluR1* (metabotropic glutamate receptor). CPPHA can potentiate responses of mGluR5 and mGluR1 to activation of these receptors. CPPHA is developed for the research of central nervous system disorders .

HY-110254

AZD 9272	mGluR	Neurological Disease
AZD 9272 is a selective, orally active and brain penetrant *mGluR5* antagonist with IC₅₀s of 2.6 nM and 7.6 nM for rat and human receptors, respectively. AZD 9272 shows >3900-fold selectivity over other mGlu receptors ^2].

HY-103571

VU0285683	mGluR	Neurological Disease
VU0285683 is a selective *mGluR5* positive allosteric modulator (PAM). VU0285683 has anxiolytic-like activity in rodent models for anxiety .

HY-103564

ACDPP	mGluR	Neurological Disease
ACDPP is a specific *mGluR5* antagonist. ACDPP partially bolcks the increase of fragile X mental retardation protein (FMRP) caused by DHPG (HY-12598A) (group I mGluR Agonist) .

HY-102094

(E/Z)-SIB-1893	mGluR	Neurological Disease
(E/Z)-SIB-1893 is a racemic compound of (E)-SIB-1893 and (Z)-SIB-1893 isomers. (E)-SIB-1893 is a selective non-competitive metabotropic glutamate subtype 5 receptor *(mGluR5)* antagonist .

HY-129636

CLH304a (E)-GABAB receptor antagonist 1	GABA Receptor ERK	Neurological Disease
CLH304a (compound 14) is a specific and noncompetitive GABA_B receptor negative allosteric modulator (NAM). CLH304a decreases GABA-induced IP3 production with an IC₅₀ of 37.9 μM. CLH304a has no effect on other GPCR Class C members such as mGluR1, mGluR2, and mGluR5. CLH304a acts on the heptahelical domain of GB2 subunits and non-competitively inhibits the effect of agonists with inverse agonist properties. CLH304a inhibits Baclofen (HY-B0007)-induced ERK1/2 phosphorylation in HEK293 cells overexpressing GABA_B receptor .

HY-107508

VU-29	mGluR	Neurological Disease
VU-29 is a positive allosteric modulator of *metabotropic glutamate 5 (mGlu5) receptor* (EC₅₀=9 nM and K_i=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC₅₀: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) .

HY-141832

mGluR5 modulator 1	mGluR	Neurological Disease
mGluR5 modulator 1 is a *mGluR5* positive allosteric modulator. mGluR5 modulator 1 can be used for the research of the schizophrenia and cognitive impairments .

HY-141848A

(S,S)-BMS-984923	mGluR	Neurological Disease
(S,S)-BMS-984923 is a less active (S,S)-enantiomer of BMS-984923. (S,S)-BMS-984923 shows an EC₅₀ >1μM for mGluR5 receptor . BMS-984923 is a potent mGluR5 silent allosteric modulator . (S,S)-BMS-984923 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103574

Raseglurant hydrochloride ADX-10059 hydrochloride	mGluR	Neurological Disease
Raseglurant hydrochloride is a negative allosteric modulator of *mGluR5*. Raseglurant hydrochloride can be used in study migraine .

HY-119282

AZD6538	mGluR	Neurological Disease
AZD6538 is a potent, selective and brain penetrant mGluR5 negative allosteric modulator. AZD6538 inhibits DHPG (HY-12598A)-stimulated intracellular Ca2+ release in HEK cells expressing rat or human mGluR5, with IC₅₀ values of 3.2 and 13.4 nM for rat mGluR5 and human mGluR5, respectively. AZD6538 can be used for the research of neuropathic pain .

HY-100728

BMT-145027	mGluR	Neurological Disease
BMT-145027 is an *mGluR5* positive allosteric modulator without inherent agonist activity, exhibits an EC₅₀ of 47 nM.

HY-110141

ABP688	mGluR	Others
ABP688 is a high affinity human mGluR5 antagonist with anK_i of 1.7 nM. Radioisotope-labeled ABP688 can be used as a PET tracer for clinical imaging of the mGlu5 receptor .

HY-W017230R

L-Cysteinesulfinic acid monohydrate (Standard)	Reference Standards mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-108034

GET73	GABA Receptor	Neurological Disease
GET73 is a γ-hydroxybutyric acid (GHB) analog, a naturally occurring neurotransmitter. GET73 has anti-alcohol and anxiolytic properties. GET73 significantly affects glutamate transmission in the hippocampus .

HY-100804R

L-Cysteinesulfinic acid (Standard)	Reference Standards mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid (Standard) is the analytical standard of L-Cysteinesulfinic acid. This product is intended for research and analytical applications. L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-16951

VU-1545	mGluR	Neurological Disease
VU-1545 is a metabotropic glutamate receptor 5 positive allosteric modulator (mGluR5 PAM) with a K_i of 156 nM and an EC₅₀ of 9.6 nM .

HY-115483

VU0477573	mGluR	Neurological Disease
VU0477573 is a brain-penetrant partial negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5). VU0477573 exhibits neuroprotective and anxiolytic effects. VU0477573 can be used for the research of neurological disease, such as Parkinson disease .

HY-123874

BMS-952048	mGluR	Neurological Disease
BMS-952048 is a positive allosteric modulator of *mGluR5* with an EC₅₀ of 10 nM .

HY-103575

MFZ 10-7	mGluR	Neurological Disease
MFZ 10-7 is a highly potent and selective *mGluR5* NAM (negative allosteric modulator), with a K_i of 0.67 nM for rat mGluR5 . MFZ 10-7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103561

DCB	mGluR	Neurological Disease
DCB (3,3′-dichlorobenzaldazine) is an neutral allosteric modulator of themetabotropic glutamate receptor metabotropic glutamate receptor subtype 5 (mGluR5) . DCB blocks the positive allosteric regulation of mGluRs (mGluR5) with the help of 3,3′-difluorobenzaldazine (DFB). DCB shows the negative modulatory effect of 3,3′-dimethoxybenzaldazine (DMeOB) .

HY-124393

GRN-529	mGluR	Neurological Disease
GRN-529 is a negative allosteric modulator (NAM) for *mGluR5*. GRN-259 modulates sleep-wake activity, and exhibits anxiolytic efficacy in rats .

HY-110255

AZD 2066 1 Publications Verification	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease ^[5].

HY-125717

VU0029251	mGluR	Neurological Disease
VU0029251 is a *mGluR5* partial antagonist (K_i: 1.07 μM). VU0029251 inhibits glutamate induced calcium mobilization in HEK293 cell membranes expressing rat mGluR5 (IC₅₀: 1.7 μM) .

HY-120641

BMS-955829	mGluR	Neurological Disease
BMS-955829 is an orally active and selective *mGluR5* positive allosteric modulator with an EC₅₀ of 2.6 nM. BMS-955829 has no intrinsic agonist activity and a low glutamate fold shift (2.4). BMS-955829 can effectively improve cognitive and executive function deficits in rodents. BMS-955829 can be used in the research of cognitive impairment diseases such as schizophrenia .

HY-15257R

Mavoglurant (Standard) AFQ056 (Standard)	mGluR Reference Standards	Neurological Disease
Mavoglurant (Standard) is the analytical standard of Mavoglurant. This product is intended for research and analytical applications. Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103575A

MFZ 10-7 hydrochloride	mGluR	Neurological Disease
MFZ 10-7 hydrochloride is a highly potent and selective *mGluR5* NAM (negative allosteric modulator), with a K_i of 0.67 nM for rat mGluR5 . MFZ 10-7 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13058B

(R)-ADX-47273	mGluR	Neurological Disease
(R)-ADX-47273 is a potent *mGluR5* positive allosteric modulator, with an EC₅₀ of 168 nM for potentiation .

Cat. No.	Product Name	Target	Research Area

HY-P1363

β-Amyloid (1-42), human TFA Maximum Cited Publications 24 Publications Verification Amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

HY-P1363A

β-Amyloid (1-42), human Maximum Cited Publications 24 Publications Verification Amyloid β-peptide (1-42) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

HY-P1363B

β-Amyloid (1-42), human, HFIP-treated Maximum Cited Publications 24 Publications Verification	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA	Isotope-Labeled Compounds Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100786

DL-AP3 1 Publications Verification	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite mGluR Phosphatase
DL-AP3 is a competitive *mGluR1* and *mGluR5* antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect .

HY-100804

L-Cysteinesulfinic acid 2 Publications Verification	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	mGluR Endogenous Metabolite
L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-W017230

L-Cysteinesulfinic acid monohydrate 2 Publications Verification	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	mGluR Endogenous Metabolite
L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-W017230R

L-Cysteinesulfinic acid monohydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards mGluR Endogenous Metabolite
L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-100804R

L-Cysteinesulfinic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards mGluR Endogenous Metabolite
L-Cysteinesulfinic acid (Standard) is the analytical standard of L-Cysteinesulfinic acid. This product is intended for research and analytical applications. L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701627

	GRM5 Protein, Human (sf9, His) GRM5; Metabotropic glutamate receptor 5; mGluR5	Human	Sf9 insect cells
	The GRM5 protein is a G protein-coupled glutamate receptor that undergoes ligand-induced conformational changes and activates signaling cascades through G proteins, affecting downstream effectors. This cascade includes the phosphatidylinositol-calcium second messenger system and induces calcium-activated chloride currents. GRM5 Protein, Human (sf9, His) is the recombinant human-derived GRM5 protein, expressed by sf9 insect cells , with C-10*His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[5] .

Host:	Mouse (2) Rabbit (2)
Reactivity:	Human (4) Rat (2) Mouse (2)
Application:	IHC-P (4) ICC/IF (4) IP (1) WB (2) FC (2) ELISA (2)
Isotype:	IgG (2) IgG1 (2)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (2) Monoclonal Antibody (1) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84310

	Metabotropic glutamate receptor 5 Antibody (YA4007) mGlu5; GPRC1E; mGluR5; PPP1R86	IHC-P, ICC/IF, ELISA	Human
	Metabotropic glutamate receptor 5 Antibody (YA4007) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Metabotropic glutamate receptor 5.

HY-P84310A

	Metabotropic glutamate receptor 5 Antibody (YA4007)(PBS only) mGlu5; GPRC1E; mGluR5; PPP1R86	IHC-P, ICC/IF, ELISA	Human
	Metabotropic glutamate receptor 5 Antibody (YA4007) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Metabotropic glutamate receptor 5.

HY-P81764

	Metabotropic glutamate receptor 5 Antibody (YA1509) GPRC1E; GRM5; Metabotropic glutamate receptor 5 precursor; mGluR5; MGR5	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	Metabotropic glutamate receptor 5 Antibody (YA1509) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Metabotropic glutamate receptor 5.

HY-P80220

	Metabotropic glutamate receptor 5 Antibody (YA297) GPRC1E; GRM5; Metabotropic Glutamate Receptor 5 precursor; mGluR5; MGR5	WB, ICC/IF, IHC-P, FC, IP	Human, Mouse, Rat
	Metabotropic glutamate receptor 5 Antibody (YA297) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Metabotropic glutamate receptor 5.